I INTELLIA THERAPEUTICS INC
| Market Cap | $1.65B |
| P/E Ratio | — |
| Forward P/E | -4.79 |
| Dividend Yield | — |
| Beta | 2.02 |
| 52W Range | $5.90 - $28.25 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 20 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| BASTA JAMESEVP, General Counsel | Sale | 1,211 | $13.78 | $16.69K | 02 Mar 2026 | 03 Mar 2026 |
| Clark ElianaEVP, Chief Technical Officer | Sale | 607 | $13.78 | $8.36K | 02 Mar 2026 | 03 Mar 2026 |
| LEONARD JOHN MPresident and CEO | Sale | 34,146 | $9.21 | $314.48K | 05 Jan 2026 | 07 Jan 2026 |
| Dube Michael PVP, Chief Accounting Officer | Sale | 2,989 | $9.21 | $27.53K | 05 Jan 2026 | 07 Jan 2026 |
| Clark ElianaEVP, Chief Technical Officer | Sale | 9,515 | $9.21 | $87.63K | 05 Jan 2026 | 07 Jan 2026 |
| Lebwohl DavidEVP, Chief Medical Officer | Sale | 11,903 | $9.21 | $109.63K | 05 Jan 2026 | 07 Jan 2026 |
| Dulac Edward J IIIEVP, Chief Financial Officer | Sale | 6,379 | $9.21 | $58.75K | 05 Jan 2026 | 07 Jan 2026 |
| Cohen Fred E | Buy | 150,000 | $9.35 | $1.40M | 05 Jan 2026 | 07 Jan 2026 |
| Schultes Birgit CEVP, Chief Scientific Officer | Sale | 8,508 | $9.21 | $78.36K | 05 Jan 2026 | 07 Jan 2026 |
| BASTA JAMESEVP, General Counsel | Sale | 10,397 | $9.21 | $95.76K | 05 Jan 2026 | 07 Jan 2026 |
| Birgit C SchultesEVP, Chief Scientific Officer | Sale | 8,508 | $9.21 | $78.36K | 05 Jan 2026 | 07 Jan 2026 |
| David LebwohlEVP, Chief Medical Officer | Sale | 11,903 | $9.21 | $109.63K | 05 Jan 2026 | 07 Jan 2026 |
| John M LeonardPresident and CEO | Sale | 34,146 | $9.21 | $314.48K | 05 Jan 2026 | 07 Jan 2026 |
| Fred E CohenDirector | Buy | 150,000 | $9.35 | $1.40M | 05 Jan 2026 | 07 Jan 2026 |
| Edward J Dulac IIIEVP, Chief Financial Officer | Sale | 6,379 | $9.21 | $58.75K | 05 Jan 2026 | 07 Jan 2026 |
| Eliana ClarkEVP, Chief Technical Officer | Sale | 9,515 | $9.21 | $87.63K | 05 Jan 2026 | 07 Jan 2026 |
| James BastaEVP, General Counsel | Sale | 10,397 | $9.21 | $95.76K | 05 Jan 2026 | 07 Jan 2026 |
| LEONARD JOHN MPresident and CEO | Sale | 5,355 | $9.59 | $51.35K | 11 Dec 2025 | 12 Dec 2025 |
| LEONARD JOHN MPresident and CEO | Sale | 32,832 | $9.47 | $310.92K | 11 Dec 2025 | 12 Dec 2025 |
| LEONARD JOHN MPresident and CEO | Sale | 49,959 | $9.49 | $474.11K | 11 Dec 2025 | 12 Dec 2025 |
Frequently Asked Questions
What is NTLA stock price today?
INTELLIA THERAPEUTICS INC (NTLA) is currently trading at $13.98. The stock has a 52-week range of $5.90 to $28.25 and a market capitalization of $1.65B.
Is NTLA a good stock to buy in 2026?
INTELLIA THERAPEUTICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +46.0%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling NTLA stock?
There have been 20 insider transactions for NTLA in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has NTLA stock performed over the past year?
INTELLIA THERAPEUTICS INC (NTLA) has returned +46.0% over the past 12 months. The stock traded between $5.90 and $28.25 during this period, and is currently at $13.98.
Which hedge funds own NTLA (INTELLIA THERAPEUTICS INC)?
0 tracked hedge funds currently hold NTLA in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is NTLA's market cap and valuation?
INTELLIA THERAPEUTICS INC (NTLA) has a market capitalization of $1.65B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is NTLA's revenue and profitability?
INTELLIA THERAPEUTICS INC reported revenue of $67.67M with net income of N/A and a profit margin of N/A. The stock has a beta of 2.02.
What sector is NTLA in and who are its biggest institutional holders?
INTELLIA THERAPEUTICS INC (NTLA) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.